参附注射液减轻Ⅲ/Ⅳ期非小细胞肺癌化疗的毒副反应及体会

Adverse reactions and experience for treating non-small cell lung cancer in stage Ⅲ/Ⅳ after chemotherapy with the Shenfu injection

目的:探讨参附注射液对DP(多西他赛+顺铂)化疗方案治疗Ⅲ/Ⅳ期非小细胞肺癌的减毒、生活质量及患者满意度的影响。方法:将78例Ⅲ/Ⅳ期非小细胞肺癌患者根据治疗情况分为实验组(参附注射液联合DP方案)39例和对照组(DP方案)39例。21d为一个周期,治疗2个周期后进行评价及调查。结果:两组毒副反应主要为骨髓抑制(以白细胞减少、血小板减少、贫血为主要表现)和胃肠道反应(以恶心/呕吐、便秘为主要表现)。实验组Ⅲ/Ⅳ度白细胞减少发生率低于对照组(0.00%VS 33.33%),差异有统计学意义(P<0.05);实验组Ⅲ/Ⅳ度血红蛋白减少发生率低于对照组(7.69%VS 15.38%),差异无统计学意义(P>0.05);胃肠道反应、血小板减少、肝肾功能异常等差异均无统计学意义。实验组的生活感受、健康感受、活动能力、日常生活能力、家庭支持评分均优于对照组,差异有统计学意义(P<0.05)。实验组患者满意度优于对照组(92%VS 66%),差异有统计学意义(P<0.05)。结论:参附注射液联合DP方案对晚期非小细胞肺癌具有减轻毒副反应,可提高患者生活质量及满意度,值得临床推广应用。

Objective:To evaluate clinical effects of the Shenfu injection on the attenuated,life quality and satisfaction of patients with non-small cell lung cancer in stageⅢ/Ⅳand received DP(docetaxel plus cisplatin)chemotherapy.Methods:78cases were divided into two groups.39patients in the control group were treated with docetaxel and cisplatin.39patients in the experimental group were given the Shenfu injection more.A course of treatment lasted for21days.Results:The main adverse reactions in groups were myelosuppression and gastrointestinal reactions.The incidence of leukopenia with gradeⅢ/Ⅳin the experimental group was lower than that in the control group(0.00%VS33.33%).The difference was statistically significant(P<0.05).The incidence of hemoglobin with gradeⅢ/Ⅳin the experimental group was lower than that in the control group(7.69%VS15.38%);there was no statistically significant difference(P>0.05).There was no statistically significant difference in gastrointestinal reaction,thrombocytopenia,liver and kidney function abnormalities.The life expectancy,health feeling,activity ability,daily living ability and family support scores in the experimental group were superior to the control group;the difference was statistically significant(P<0.05).The satisfaction in the experimental group was better than that in the control group(92%VS66%),and the difference was statistical significant(P<0.05).Conclusion:The Shenfu injection plus DP regimen can reduce the side effects,improve life quality and the satisfaction of patients with advanced NSCLC,and is worthy to be popularized.